Summary of the Conference Call for 康龙化成 (Kanglong Chemical) Company Overview - 康龙化成 is a leading player in the pharmaceutical and biotechnology services industry, focusing on laboratory services, small molecule CDMO (Contract Development and Manufacturing Organization), and clinical services. Key Financial Highlights - In 2025, the company achieved revenue of 140.95 billion CNY, a year-on-year increase of 14.8% [3] - Adjusted net profit was 18.16 billion CNY, up 13% year-on-year, while net profit attributable to shareholders decreased by 7.2% due to significant investment gains in 2024 [3] - Revenue from the top 20 global pharmaceutical companies grew by 29.4%, accounting for 20% of total revenue [3] - New orders increased by over 14% year-on-year, with more than 950 new clients contributing approximately 4% to revenue [3] Business Segment Performance Laboratory Services - Revenue reached 81.59 billion CNY, a 15.8% increase year-on-year, with a gross margin of 44.7% [5] - The segment participated in 887 global new drug discovery projects, showing an increase from 2024 [5] - The growth was driven by the integration of AI and automation technologies, enhancing research efficiency [5] Small Molecule CDMO - Revenue was 34.83 billion CNY, up 16.5% year-on-year, with a gross margin of 33.8% [6] - The segment saw significant order growth, particularly in the second half of the year, with Q4 revenue reaching 11.9 billion CNY [6] - The number of late-stage projects increased significantly, with 47 Phase III projects and 34 commercial projects [7] Clinical CRO Services - The clinical business saw a slight increase in new orders, with overseas business achieving double-digit growth, accounting for over 35% of total revenue [14] - Domestic CRO and SMO services showed modest growth, with signs of price recovery in the market [14] Strategic Developments - The company made significant strides in commercialization, with API production facilities in Ningbo and Shaoxing passing FDA inspections, leading to the approval of its first commercial API for the U.S. market [3][12] - A major commercial agreement was signed with a multinational corporation for the production of oral small molecule GLP-1 formulations [3] - The ADC (Antibody-Drug Conjugate) production facility has been launched, and a new large-scale peptide API solid-phase synthesis facility is expected to be completed by 2026 [6][11] Market Outlook - For 2026, the company projects revenue growth of 12% to 18%, with a strong order pipeline and expected acceleration in CDMO revenue growth [8][15] - The company anticipates that the CDMO segment will continue to outpace overall company growth, with further improvements in revenue share and profitability [8][10] - The company is well-positioned to leverage its integrated service platform and technological advancements to attract more clients and enhance service delivery [15] Risks and Challenges - Potential impacts from currency fluctuations, particularly the appreciation of the RMB against the USD, are acknowledged, but the company expects revenue growth to offset these effects [8][15] - The clinical business may still be influenced by low-priced orders signed in previous years, affecting revenue in 2026 [14] Conclusion - 康龙化成 demonstrated robust growth in 2025, with strong performances across its core business segments. The company is optimistic about its future prospects, driven by a solid order backlog and strategic partnerships, despite facing some external economic challenges [16][17]

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 136.15 CNY per share [6][9]. Core Views - The company reported a revenue of 6.67 billion CNY and a net profit attributable to shareholders of 1.13 billion CNY for 2025, representing year-on-year growth of 14.91% and 19.35% respectively [1][2]. - The company is expected to achieve a revenue growth of 19%-22% in 2026 due to continuous order growth and improving operational conditions [2][3]. - The total order backlog reached 1.385 billion USD, a year-on-year increase of 31.65%, with significant growth in orders for chemical and biological macromolecule CDMO services [3]. - The company is actively expanding its production capacity, with plans to increase the total capacity for peptide solid-phase synthesis from 45,000L to 69,000L by the end of 2026 [3]. - The company has a rich pipeline of mid-to-late stage projects, with expectations for multiple commercialized projects in both small molecule CDMO and emerging business sectors in 2026 [4]. Financial Summary - The projected net profits for the company from 2026 to 2028 are 1.40 billion CNY, 1.74 billion CNY, and 2.21 billion CNY, reflecting year-on-year growth rates of 23.8%, 24.3%, and 27.0% respectively [5]. - The company’s earnings per share (EPS) for 2026 is estimated to be 3.89 CNY, with a price-to-earnings (PE) ratio of 35 times, leading to a target price of 136.15 CNY per share [9]. - The company’s revenue is expected to grow from 5.8 billion CNY in 2024 to 12.46 billion CNY in 2028, with a compound annual growth rate (CAGR) of 23.0% [10][11].

Group 1: Financial Performance - Revenue reached RMB 14,095 million, with a year-over-year growth of 14.8% [14] - Non-IFRS net profit was RMB 1,816 million, reflecting a year-over-year growth of 13.0% [14] - Net profit declined to RMB 1,664 million, a year-over-year decrease of 7.2% [14] - Revenue from the top 20 multinational corporations (MNCs) grew by 29.4% [14] Group 2: Customer and Market Expansion - Over 950 new customers acquired, totaling over 3,300 active customers, including all top 20 MNCs [15] - Revenue from China entities grew by 15.0%, while overseas subsidiaries saw a growth of 13.8% [21] - New purchase orders (POs) increased by 14% year-over-year [14] Group 3: Operational Highlights - 28 R&D and manufacturing facilities across China, the UK, the US, and Singapore [15] - 887 drug discovery projects currently in progress [16] - 1,397 clinical research organization (CRO) projects, including 125 in Phase III [16] Group 4: Future Outlook - Expected revenue growth of 12-18% year-over-year in 2026 [45] - Continued development of an end-to-end, fully integrated services platform [45] - Focus on advancing the contract development and manufacturing organization (CDMO) business model and integrating AI and automation [45] Group 5: ESG and Sustainability - Achieved an MSCI ESG rating of AA and recognized as a low-risk company by Sustainalytics [23] - Joined the United Nations Global Compact (UNGC) and received the EcoVadis Silver Prize [24]

Group 1: Financial Performance - Revenue reached CNY 14.095 billion, a year-on-year increase of 14.8% [13] - Non-IFRS adjusted net profit was CNY 1.816 billion, up 13.0% year-on-year [13] - Net profit decreased to CNY 1.664 billion, a decline of 7.2% year-on-year [13] - Revenue from TOP 20 pharmaceutical clients grew by 29.4% [13] - New orders increased by over 14% year-on-year [13] Group 2: Business Segments - Revenue composition: 88% from China delivery business, 12% from overseas [16] - Laboratory services accounted for 58% of total revenue [16] - Small molecule CDMO services contributed 25% [16] - Clinical research services made up 14% [16] - Large molecule and CGT services represented 3% [16] Group 3: Client Growth - Global client revenue: North America up 11.0%, Europe up 27.4%, China up 15.7% [17] - Revenue from existing clients increased by 11.7% [19] - New clients accounted for 4% of total revenue [20] Group 4: Operational Highlights - Participated in 887 drug discovery projects [28] - 1,397 ongoing clinical research projects, including 125 Phase III trials [32] - 19 gene therapy CDMO projects, including 1 Phase III and 9 Phase I/II projects [33] Group 5: Future Outlook - The company aims for a revenue growth of 12-18% year-on-year by 2026 [49] - Focus on enhancing CDMO business model and integrating AI and automation technologies [49] - Commitment to sustainable development and improving ESG ratings [21][22]

Group 1: Coal and Aluminum Industry - Shenhua Co., Ltd. (000933.SZ) - The aluminum segment has seen a rise in both volume and price, which offsets the decline in coal prices, highlighting the company's high dividend value [7][8] - In 2025, the company achieved a revenue of 41.241 billion yuan, a year-on-year increase of 7.47%, while the net profit attributable to shareholders was 4.005 billion yuan, a decrease of 7.00% [7] - The company plans to distribute a cash dividend of 8.00 yuan per 10 shares, totaling 1.787 billion yuan, which represents 51.0% of the net profit attributable to shareholders [9] Group 2: Food and Beverage Industry - New Dairy Industry (002946.SZ) - In 2025, the company reported a revenue of 11.23 billion yuan, a year-on-year increase of 5.3%, and a net profit of 731 million yuan, up 36.0% [11][12] - The company has adjusted its net profit forecasts for 2026 and 2027 to 865 million and 975 million yuan, respectively, with an EPS of 1.00 and 1.13 yuan [12][13] - The company plans to distribute a cash dividend of 3.8 yuan per 10 shares, resulting in a cumulative dividend rate of 53% for 2025 [12] Group 3: Pharmaceutical Industry - WuXi AppTec (603259.SH) - In 2025, the company achieved a revenue of 45.456 billion yuan, a year-on-year increase of 15.8%, and a net profit of 19.151 billion yuan, up 102.7% [16][19] - The adjusted net profit margin reached 32.9%, an increase of 5.9 percentage points year-on-year [16] - The company expects to achieve a revenue of 51.3 to 53.0 billion yuan in 2026, with a focus on accelerating its CRDMO core strategy [19] Group 4: Technology Industry - Mingyuan Cloud (00909.HK) - The company reported a revenue of 1.284 billion yuan in 2025, a year-on-year decline of 10.5%, but the adjusted net profit turned positive at 101 million yuan [22] - The company has adjusted its revenue forecast for 2026 and 2027 to 1.22 billion and 1.21 billion yuan, respectively [21][22] - The AI and overseas business segments are expected to provide significant growth opportunities despite current pressures in the real estate market [21] Group 5: Textile and Light Industry - Leshu (02698.HK) - The company achieved a revenue of 567 million USD in 2025, a year-on-year increase of 24.9%, and a net profit of approximately 121 million USD, up 27.4% [26][27] - The company has raised its net profit forecasts for 2026 and 2027 to 142 million and 165 million USD, respectively [27] - The company continues to optimize its product structure and expand its market presence, particularly in high-margin categories [28] Group 6: Pharmaceutical Industry - China Resources Jiangzhong (600750.SH) - The company reported a revenue of 4.220 billion yuan in 2025, a year-on-year decrease of 4.87%, while the net profit increased by 15.03% to 907 million yuan [31] - The gross margin improved to 65.37%, an increase of 1.85 percentage points year-on-year [31][32] - The company expects to achieve net profits of 1.008 billion, 1.131 billion, and 1.242 billion yuan for 2026, 2027, and 2028, respectively [31][33] Group 7: Banking Industry - CITIC Bank (601998.SH) - The bank achieved a revenue of 212.5 billion yuan in 2025, a year-on-year decline of 0.55%, with a net interest margin of 1.63% [36][37] - The bank's net profit for Q4 2025 was 17.227 billion yuan, a year-on-year increase of 2.85% [36] - The bank plans to increase its cash dividend to 21.2 billion yuan, representing 31.75% of the net profit attributable to ordinary shareholders, marking a historical high [38] Group 8: Retail and Service Industry - Laopu Gold (06181.HK) - The company reported a revenue of 27.303 billion yuan in 2025, a year-on-year increase of 221.0%, and a net profit of 4.868 billion yuan, up 230.5% [40][41] - The company expects to achieve a revenue of 16.5 to 17.5 billion yuan in Q1 2026, with a net profit of 3.6 to 3.8 billion yuan [40] - The company is focusing on product innovation and channel optimization to enhance brand positioning and market presence [41]

Investment Rating - The report assigns an "Accumulate" rating for the company [10]. Core Insights - The company is a leading, technology-driven CDMO service provider with a strong foundation in small molecule CDMO and is exploring emerging businesses. It has established strong collaborative ties with multiple multinational corporations (MNCs) [20][21]. - The company has a stable shareholding structure and an experienced management team, which has implemented a restricted stock incentive plan to deeply bind core employees [23][28]. - As the impact of large orders gradually diminishes, the company's revenue and profit are expected to return to growth in the first three quarters of 2025 [31]. Summary by Relevant Sections Company Overview - The company provides one-stop services for over 1,100 clients globally, accelerating the clinical research and commercialization of innovative drugs. It is ranked among the top CDMO companies worldwide and is the largest commercial-stage chemical drug CDMO in China [20][21]. - The company has established R&D and production bases in multiple countries, including China, the USA, and the UK, covering various business areas such as chemical small molecules, TIDES, biopharmaceuticals, and formulation [20][21]. Small Molecule CDMO - The global small molecule CMO/CDMO industry is accelerating, with a market size projected to grow from USD 23.5 billion in 2015 to USD 52.1 billion by 2024, reflecting a CAGR of 9.2% [46]. - The company has been deeply engaged in the small molecule CDMO sector for over 20 years, providing comprehensive services throughout the drug development lifecycle [49]. - Excluding the impact of large orders, the company's small molecule CDMO revenue has been steadily increasing, with a CAGR of 15.0% from 2021 to 2024 [50]. Emerging Businesses - The company is actively expanding into emerging businesses, creating a one-stop custom service platform for innovative drugs. This includes growth in areas such as peptide and oligonucleotide CDMO, with significant market potential [8][7]. - The company has established a robust pipeline in the peptide sector, driven by rapid growth in the weight loss drug market, and is focusing on advancing its oligonucleotide CDMO capabilities [8][7]. Financial Performance and Forecast - The company expects EPS of RMB 3.15, 3.65, and 4.28 for 2025, 2026, and 2027, respectively, with a PE ratio of 27.27 for 2026 [10]. - The company's revenue is projected to recover, with a forecasted revenue of RMB 6.61 billion in 2025, reflecting a 13.9% increase from the previous year [12].

Investment Rating - The investment rating for the company is "Buy" (首次) [1] Core Insights - The company is a leading small molecule CDMO with over 25 years of experience, currently transitioning from a single small molecule business to a dual-driven model of "small molecule + emerging business" [5][17] - The new business segment is experiencing rapid growth, contributing significantly to revenue, while traditional business remains resilient [5][6] - The company is expected to achieve net profits of 1.16 billion, 1.30 billion, and 1.51 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 3.23, 3.59, and 4.18 yuan [5] Financial Summary and Valuation Metrics - Revenue projections for 2025, 2026, and 2027 are 6.66 billion, 7.69 billion, and 8.94 billion yuan respectively, with year-over-year growth rates of 14.7%, 15.4%, and 16.3% [8] - The company’s gross margin is projected to be around 42% for 2025, with a net margin of 17.5% [8] - The current P/E ratios are 31.0, 27.8, and 23.9 for 2025, 2026, and 2027 respectively [8] Business Development and Strategy - The company is focusing on expanding its capabilities in the peptide and small nucleic acid sectors, with significant investments in production capacity [6][79] - As of H1 2025, the new business segment generated 756 million yuan in revenue, a 51.22% increase year-over-year, accounting for 23.71% of total revenue [6] - The company has established partnerships with major pharmaceutical companies, enhancing its market presence and customer base [44] Industry Trends - The global healthcare investment environment is gradually recovering, with a total investment of 63.88 billion USD in 2025, marking a 10.13% increase year-over-year [47] - The domestic healthcare investment market is also improving, with a total of 73.78 billion yuan in 2025, a 39.05% increase year-over-year [53] - The global CDMO market is expected to grow significantly, with the small molecule CDMO/CMO market projected to reach 112 billion USD by 2029, growing at a CAGR of 16.6% [65]

Core Insights - WuXi AppTec (603259.SH/2359.HK) presented at the 44th JPM Healthcare Conference, updating on its business progress [1] Group 1: Business Development - The company’s small molecule API synthesis capacity reached 4 million liters by the end of 2025, indicating a robust commercial supply system built over 25 years [1] - As of Q3 last year, WuXi AppTec's small molecule CDMO pipeline totaled 3,430, with 80 commercial molecules, representing 16% of the global clinical stage small molecule new drugs [1] Group 2: Financial Performance - WuXi AppTec expects a revenue of approximately 45.456 billion yuan for the full year 2025, reflecting a year-on-year growth of 15.84%, with a 21.4% increase in revenue from continuing operations [1] - The company anticipates a significant profit increase, with net profit attributable to shareholders expected to be around 19.151 billion yuan, a substantial year-on-year growth of 102.65% [1] - Adjusted non-IFRS net profit is projected at approximately 14.957 billion yuan, a year-on-year increase of 41.33%, while the net profit after deducting non-recurring items is expected to be about 13.241 billion yuan, up 32.56% year-on-year [1] - The pre-announcement data indicates that WuXi AppTec will achieve historical highs in revenue and the three profit metrics for 2025 [1]

Core Insights - WuXi AppTec (603259.SH/2359.HK) presented at the 44th JPM Healthcare Conference, updating on its business progress [1] Business Development - The company’s small molecule API synthesis capacity reached 4 million liters by the end of 2025, indicating a robust commercial supply system built over 25 years [1] - As of Q3 last year, WuXi AppTec's small molecule CDMO pipeline totaled 3,430, with 80 commercial molecules, representing 16% of the global clinical stage small molecule new drugs [1] Financial Performance - WuXi AppTec expects a revenue of approximately 45.456 billion yuan for the full year 2025, a year-on-year increase of 15.84%, with a 21.4% growth in continuing operations revenue [1] - The profit performance is particularly strong, with a projected net profit attributable to shareholders of about 19.151 billion yuan, a significant year-on-year increase of 102.65% [1] - Adjusted non-IFRS net profit is expected to be around 14.957 billion yuan, up 41.33% year-on-year, while the net profit after deducting non-recurring items is projected at approximately 13.241 billion yuan, a 32.56% increase year-on-year [1] - The pre-announcement data indicates that WuXi AppTec will achieve historical highs in revenue and the three profit metrics for 2025 [1]

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - The company reported a revenue of 46.30 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 11.82%, with a net profit attributable to shareholders of 8.00 billion yuan, up 12.66% year-on-year [1]. - In Q3 2025, the company achieved a revenue of 14.4 billion yuan, a slight decline of 0.09% year-on-year, with the small molecule business revenue declining over 20% year-on-year, while emerging businesses saw a significant growth of 114% year-on-year [2]. - The company expects a revenue growth of 13% to 15% for the full year 2025, translating to an estimated revenue of 65.6 to 66.8 billion yuan, with Q4 revenue projected to be between 19.3 and 20.5 billion yuan, indicating a year-on-year growth of 15.9% to 22.9% [2]. Summary by Sections Financial Performance - For Q1-Q3 2025, the company achieved a revenue of 46.30 billion yuan and a net profit of 8.00 billion yuan, with a non-GAAP net profit of 7.28 billion yuan [1]. - The company’s Q3 revenue was 14.4 billion yuan, with a decline in small molecule business revenue but a doubling in emerging business revenue [2]. Future Outlook - The company is focused on expanding its market presence, with new orders showing double-digit growth, which adds certainty to future performance [2]. - The company anticipates a significant increase in Q4 deliveries compared to Q3, supporting the revenue growth guidance for 2025 [2]. Investment Recommendations - The company is positioned as a leading domestic small molecule CDMO supplier, with ongoing enhancements in its integrated service capabilities in small molecules and continued investment in large and biological molecules [3]. - Adjusted revenue forecasts for 2025-2027 are 66.09 billion, 77.48 billion, and 89.30 billion yuan, respectively, with EPS estimates revised to 3.05, 3.66, and 4.50 yuan [3].